Related Experiment Video
Updated: Mar 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings
Bérénice Charriere1, Fabrice Muscari1, Charlotte Maulat1
1Service de chirurgie digestive et hépatobiliaire, Centre Hospitalier Universitaire Rangueil, Université Paul Sabatier III, Toulouse, France.
Insights
Overall survival rates for hepatocellular carcinoma (HCC) curative treatments were similar on an intention-to-treat (ITT) basis. Key negative prognostic factors included not adhering to multidisciplinary team (MDT) decisions and elevated alpha-fetoprotein levels.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Curative treatment options for HCC include liver transplantation (LT), radiofrequency ablation (RFA), and surgical resection (SR).
- Assessing treatment efficacy on an intention-to-treat (ITT) basis is crucial for clinical decision-making.
Purpose of the Study:
- To compare overall survival (OS) rates for LT, RFA, and SR in HCC patients.
- To evaluate the impact of multidisciplinary team (MDT) decisions on treatment outcomes.
- To identify prognostic factors influencing survival in HCC patients undergoing curative treatment.
Main Methods:
- A cohort study was conducted using data from an HCC-dedicated multidisciplinary team meeting (MDT).
- Patients diagnosed with HCC between 2006 and 2013, with a decided curative treatment (LT, RFA, or SR), were included.
- Overall survival (OS) was analyzed on an intention-to-treat (ITT) basis.
Main Results:
- Five-year OS rates on an ITT basis were comparable across LT (35%), RFA (32%), and SR (34%) groups (P=0.77).
- Sixty-six percent of patients received their planned curative treatment.
- Multivariate analysis identified non-adherence to MDT decisions (HR: 0.39), elevated alpha-fetoprotein (HR: 0.63), and exclusion from Milan criteria (HR: 0.45) as negative prognostic factors.
Conclusions:
- Intention-to-treat (ITT) overall survival (OS) was similar for liver transplantation (LT), radiofrequency ablation (RFA), and surgical resection (SR) in hepatocellular carcinoma (HCC).
- Adherence to multidisciplinary team (MDT) recommendations is critical for improving patient outcomes.
- Elevated alpha-fetoprotein levels and exceeding Milan criteria significantly worsen prognosis in HCC patients.
Background And Objectives:
To analyze overall survival (OS) rates for the three curative treatments of hepatocellular carcinoma (HCC) on an intention-to-treat (ITT) basis.
Methods:
Cohort study based on data from a multidisciplinary team meeting (MDT) dedicated to HCC. From 2006 to 2013, we included every patient with newly diagnosed HCC, for whom curative treatment (liver transplantation (LT), radiofrequency ablation (RFA), surgical resection (SR)) was decided upon.
Results:
We included 387 consecutive patients. LT was decided in 136 cases, RFA in 131 cases, SR in 120 cases. Sixty-six percent of patients received the planned treatment. Five-year OS on an ITT basis were: 35% for the LT-group, 32% for the RFA-group, 34% for the SR-group (P = 0.77). In multivariate analyses, the main negative prognostic factors were not following the MDT decision (HR: 0.39, CI95% [0.27-0.54], P < 0.001), elevated alpha-fetoprotein level (HR: 0.63, CI95% [0.45-0.87], P = 0.005), being outside the Milan criteria (HR: 0.45, CI95% [0.31-0.65], P < 0.001). When curative treatment was performed, per-protocol 5-year OS were 64% for LT, 34% for RFA, 40% for SR.
Conclusion:
On an ITT basis, OS was similar whatever the type of curative treatment chosen in MDT. Negative prognostic factors were not following the MDT decision, elevated alpha-fetoprotein, being outside the Milan criteria. J. Surg. Oncol. 2017;115:330-336. © 2016 Wiley Periodicals, Inc.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...